Literature DB >> 14996860

Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia.

Weimin Ye1, Maria Held, Jesper Lagergren, Lars Engstrand, William J Blot, Joseph K McLaughlin, Olof Nyrén.   

Abstract

BACKGROUND: An inverse association between Helicobacter pylori infection and esophageal adenocarcinoma has been reported that may be attributed to reduced acidity from inducing atrophic gastritis and from producing ammonia. We examined associations between H. pylori infection, gastric atrophy, and the risk of esophageal adenocarcinoma, esophageal squamous-cell carcinoma, and gastric cardia adenocarcinoma in a large population-based case-control study in Sweden.
METHODS: Self-reported data were obtained during interviews, and serum was collected from 97 patients with incident esophageal adenocarcinoma, 85 patients with incident esophageal squamous-cell carcinoma, 133 patients with incident gastric cardia adenocarcinoma, and 499 randomly selected control subjects. Serum antibodies against whole H. pylori cell-surface antigens (HP-CSAs) and cytotoxin-associated gene A (CagA) antigens were assessed by an IgG enzyme-linked immunosorbent assay and immunoblotting, respectively. Gastric atrophy was assessed by serum levels of pepsinogen I. Multivariable logistic regression with adjustment for potential confounding factors was used to evaluate associations.
RESULTS: H. pylori infection, assayed by HP-CSA or CagA antibodies, was statistically significantly associated with a reduced risk for esophageal adenocarcinoma (for HP-CSA antibodies, odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.2 to 0.6; for CagA antibodies, OR = 0.5, 95% CI = 0.3 to 0.8; for both, OR = 0.2, 95% CI = 0.1 to 0.5). Gastric atrophy was not associated with the risk for esophageal adenocarcinoma (OR = 1.1, 95% CI = 0.5 to 2.5). Serum CagA antibodies and gastric atrophy were associated with an increased risk for esophageal squamous-cell carcinoma (OR = 2.1, 95% CI = 1.1 to 4.0, and OR = 4.3, 95% CI = 1.9 to 9.6, respectively). The risk of gastric cardia adenocarcinoma was not associated with H. pylori infection. However, gastric atrophy was associated with an increased risk for gastric cardia adenocarcinoma (OR = 4.5, 95% CI = 2.5 to 7.8).
CONCLUSIONS: Infection with H. pylori may reduce the risk of esophageal adenocarcinoma, but it is unlikely to do so by atrophy-reduced acidity. Gastric atrophy and infection with CagA-positive strains of H. pylori may increase the risk for esophageal squamous-cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996860     DOI: 10.1093/jnci/djh057

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  115 in total

1.  Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer?

Authors:  Shyam Menon; Peter Nightingale; Nigel Trudgill
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 2.  Barrett esophagus: an update.

Authors:  Rami J Badreddine; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 46.802

3.  Gastroesophageal reflux disease: Important considerations for the older patients.

Authors:  Maxwell M Chait
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

4.  Serum pepsinogens and Helicobacter pylori in relation to the risk of esophageal squamous cell carcinoma in the alpha-tocopherol, beta-carotene cancer prevention study.

Authors:  Michael B Cook; Sanford M Dawsey; Lena Diaw; Martin J Blaser; Guillermo I Perez-Perez; Christian C Abnet; Philip R Taylor; Demetrius Albanes; Jarmo Virtamo; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

5.  Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

Authors:  Yi-Chia Lee; Jyh-Ming Liou; Ming-Shiang Wu; Chun-Ying Wu; Jaw-Town Lin
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

Review 6.  Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?

Authors:  J Lagergren
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

7.  H pylori receptor MHC class II contributes to the dynamic gastric epithelial apoptotic response.

Authors:  David A Bland; Giovanni Suarez; Ellen J Beswick; Johanna C Sierra; Victor E Reyes
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

Review 8.  Helicobacter pylori and oesophageal cancer--not always protective.

Authors:  Kenneth E L McColl
Journal:  Gut       Date:  2007-04       Impact factor: 23.059

9.  Helicobacter pylori and esophageal cancer risk: a meta-analysis.

Authors:  Farhad Islami; Farin Kamangar
Journal:  Cancer Prev Res (Phila)       Date:  2008-10

10.  Gastric hyposecretion in esophageal squamous-cell carcinomas.

Authors:  K Iijima; T Koike; Y Abe; H Yamagishi; N Ara; K Asanuma; K Uno; A Imatani; N Nakaya; S Ohara; T Shimosegawa
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.